Jia-Jun Liu

Jia-Jun Liu

Auto-generated profile, based on publicly available information

Jia-Jun Liu

Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Cancer Research Communications
Verified
Journal Article
Open access
MKMinwook Kim
Minwook Kim
YPYoojeong Park
Yoojeong Park
RCRachel Covitz
Rachel Covitz
JKJoseph Kwon
Joseph Kwon
JLJia-Jun Liu
Jia-Jun Liu
SKSungjin Ko
Sungjin Ko
Hepatocytes (HC), which share a developmental origin with cholangiocytes (CC), have the capacity to undergo reparative reprogramming into CCs in response to liver injury and, under specific conditions, can also transform malignantly into cholangiocarcinoma (CCA). However, the molecular mechanisms governing HC plasticity in liver diseases remain poorly understood. In this study, we investigated the role of spalt-like transcription factor 4 (SALL4), an oncofetal transcription factor, in both malignant and regenerative HC fate transitions toward the biliary lineage. Using Sleeping Beauty hydrodynamic tail vein injection–mediated murine liver cancer models, we explored HC-to-CCA transformation, whereas the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet–induced cholestasis model was used to investigate regenerative HC-to-CC reprogramming. Our findings reveal that SALL4 is specifically required for myristoylated Akt–YAP1S127A-driven HC-to-CCA transformation, as its loss significantly suppressed malignant reprogramming and clonal expansion. Surprisingly, Sall4 overexpression also prevented YAP1S127A-driven CCA development while promoting the expansion of liver progenitor cell (LPC)-like fatty HCs. Mechanistically, we propose Bmi1 as a key downstream effector of SALL4 in YAP1-dependent HC-to-CCA transformation. Additionally, in the DDC–fed cholestasis model, Sall4 deletion enhanced HC-to-LPC activation while impairing LPC differentiation into mature CCs. These findings establish SALL4 as a critical regulator of HC plasticity in both malignant and regednerative contexts and highlight its potential as a therapeutic target for specific liver cancer subtypes. Significance: HC plasticity supports repair but can drive malignancy, acting as a double-edged sword. We identify SALL4 as regulator of YAP1-driven HC-to-CC reprogramming, revealing the YAP1–SALL4–BMI1 axis as a therapeutic target for CCA.

12 May 2026 in The American Journal of Pathology
Verified
Journal Article
Open access
SBSHEHNAZ BANO
SHEHNAZ BANO
MCMatthew A. Copeland
Matthew A. Copeland
JLJia-Jun Liu
Jia-Jun Liu
AOAnne Orr
Anne Orr
JSJohn W. Stoops
John W. Stoops
Bharat BhushanBharat Bhushan
Bharat Bhushan
Systemic PPARγ agonist therapies have been investigated for clinical use in MASLD. Previous studies, however, have shown that PPARγ activation in hepatocytes worsens MASLD. Overall, the precise molecular mechanisms regulated by PPARγ in hepatocyte during MASLD remain incompletely defined. Hepatocyte-specific PPARγ knockout mice were fed a clinically-relevant fast-food diet (FFD) for 2 or 5-months to characterize the role of PPARγ in MASLD progression. PPARγ expression and activity were increased in murine FFD-model and in hepatocytes of human MASLD/MASH patients, based on single-nucleus RNA-sequencing analysis. PPARγ-deletion conferred protection against diet-induced steatosis, fibrosis, and liver injury by suppressing lipogenic, inflammatory, and fibrogenic signaling. Although de-novo fatty-acid synthesis was only modestly affected and compensated with disease progression, enhancement of lipolysis and suppression of lipid droplet stabilization machinery was persistent. PPARγ-deletion robustly inhibited expression and signaling-activity of TGFβ1, a master regulator of hepatic fibrosis, throughout the progression of MASLD. Importantly, a novel PPARγ-HNF4α regulatory axis in MASLD was identified, with increased HNF4α mRNA/protein expression and activation of its downstream metabolic networks in PPARγ-deficient livers. Further, integration of ChIP-seq and transcriptomic analysis revealed that HNF4α might be co-regulating a major fraction (>70%) of genes under direct control of PPARγ during MASLD. This study provides a comprehensive temporal framework for hepatocyte PPARγ function in MASLD, revealing an antagonistic PPARγ-HNF4α transcriptional network that governs hepatic metabolic fate.

29 January 2026 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
XZXianke Zhou
Xianke Zhou
YGYuan Gui
Yuan Gui
JLJia-Jun Liu
Jia-Jun Liu
SLShijia Liu
Shijia Liu
DLDongning Liang
Dongning Liang
HFHaiyan Fu
Haiyan Fu
Diabetic kidney disease (DKD) progresses to end-stage renal disease more rapidly than chronic kidney disease due to persistent hyperglycemia and early activation of multiple pathways. Early detection of DKD is crucial to identify subtle kidney damage before clinical symptoms appear. This study combined human serum proteomics and public single-cell RNA sequencing and spatial transcriptomics data from diabetic kidneys to identify key biomarkers for DKD diagnosis. These biomarkers were validated in multiple organs of db/db mice at early and advanced stages. In a discovery cohort, sera from 173 healthy adults and 444 type 2 diabetes mellitus (T2DM) patients, with or without kidney disease, were analyzed using metabolomics and enzyme-linked immunosorbent assay (ELISA). Multiple machine learning algorithms were developed to integrate synergistic biomarkers and serum metabolites for DKD early detection, with results validated in 435 participants from four independent clinical cohorts. Metalloproteinase-7 (MMP-7) and tenascin C (TNC) were elevated in human diabetic kidneys at the single-cell and spatial levels. Proteomics indicated upregulation of serum amyloid A1 (SAA1) and TNC in DKD patients' serum. In db/db mice, all three biomarkers increased in multiple organs by 18 weeks of age. In DKD patient sera, MMP-7 and TNC levels were consistently elevated across cohorts. The new algorithms combining MMP-7, SAA1, and TNC enhanced early-stage DKD detection, with about 13% improvements in accuracy when serum metabolites were included to distinguish the progression from early to advanced stages after DKD. Integrating synergistic biomarkers with serum metabolomics enhances early detection of DKD, potentially improving outcomes by slowing disease progression in T2DM patients.

5 August 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
CMCamila Macedo
Camila Macedo
YHYannis Hadjiyannis
Yannis Hadjiyannis
LTLillian M. Tran
Lillian M. Tran
BEBeth D. Elinoff
Beth D. Elinoff
IAIbrahim M. Abukhiran
Ibrahim M. Abukhiran
ATAngus W. Thomson
Angus W. Thomson
Subclinical rejection after liver transplantation precludes immunosuppression withdrawal despite normal clinical function. To better understand the immunobiology of early subclinical rejection, we performed longitudinal, multimodal immune profiling and single-cell RNA sequencing (scRNA-seq) in adult living-donor recipients ( n = 13) participating in an interventional immunosuppression withdrawal trial. Samples from patients with subclinical rejection (termed “nonpermissive”) at 12 months posttransplant exhibited distinct immune trajectories from those with quiescent (“permissive”) allografts despite comparable baseline profiles. Central to these distinct dynamics was biphasic Janus kinase (JAK)–signal transducer and activator of transcription (STAT)–interferon signaling. Greater interferon-stimulated gene (ISG) expression and JAK-STAT activation occurred postreperfusion in permissive allograft recipients, which reversed at 12 months, when elevated ISG expression and JAK-STAT signaling were evident in nonpermissive recipients exhibiting subclinical rejection. We then leveraged our findings to ascertain whether a comparable signature existed in internal and external bulk RNA-seq and scRNA-seq liver transplant cohorts. Across cohorts, including a rodent model, there was a similar elevation in JAK-STAT signaling in instances of allograft rejection. We also detected distinct, portal-based phosphorylated STAT1 staining in a preliminary analysis of biopsies exhibiting histologic rejection compared with nonrejecting controls. Moreover, ruxolitinib-mediated JAK inhibition suppressed alloreactive CD8 + T cell proliferation and inflammatory-mediator production in vitro. Together, these exploratory findings suggest a temporal, biphasic role for JAK-STAT signaling in the regulation and occurrence of T cell–mediated rejection after liver transplant and highlight JAK inhibition as a potential therapeutic strategy.

26 June 2026 in Science Advances
Verified
Journal Article
Open access
SSSerrena Singh
Serrena Singh
NTNareh Tahmasian
Nareh Tahmasian
JLJia-Jun Liu
Jia-Jun Liu
WWWenjia Wang
Wenjia Wang
LHLucas Haas
Lucas Haas
DYDean Yimlamai
Dean Yimlamai
YAP and its paralog, TAZ , are transcriptional coactivators of the Hippo pathway that regulate cell growth. Their structural distinctiveness suggests important independent functional differences. To investigate this further, we generated YAP- and TAZ-predominant clones in the liver and followed their long-term behavior. YAP clones rapidly dedifferentiate cells into a stem cell–like state with inflammatory immune cell recruitment followed by their clearance. In contrast, TAZ clones promote an anti-inflammatory immune environment, resulting in their long-term maintenance, massive organ growth, and increased mortality. YAP clones recruit inflammatory blood-derived monocytes, which, if inhibited, permits YAP clonal growth. Consistent with these results, patients with YAP High colorectal cancer (CRC) had a 67% 5-year survival rate, whereas patients with TAZ High CRC did not survive to 5 years. Similar trends were seen in patients with hepatocellular carcinoma. These findings underscore the importance of understanding the intrinsic differences in YAP and TAZ biology as independent drivers of disease.